Tradestie Institutional Equity Comparison Engine

REGN vs GNPX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, REGN trades at 14.8x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus GNPX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against GNPX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
REGN 14.8x vs GNPX N/M Fwd P/E
Growth & Margin Winner REGN
Op Margin 30.4% vs 0.0% ยท YoY +36.3% vs +0.0%
Momentum & Technical Winner REGN
1Y +31.0% vs -56.6% ยท 52W Pos 82% vs 11%
Options & Structure Winner REGN
CONSOLIDATION (6th %ile IV) vs UNCLASSIFIED (N/A IV)
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$920.69
-0.29% 1D
Market Cap $95.5B
1M Return +12.4%
1Y Return +31.01%
Forward P/E 14.8x
Unified AI Score
46.0 / 100 HOLD
Tech 29.0 Fund 49.0 Flow 69.0 Mom 56.0
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
1M Return -26.77%
1Y Return -56.59%
Forward P/E N/M
Unified AI Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REGN +31.01% GNPX -56.59% Spread: +87.6 pp (REGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
REGN TTM Op. Margin: 30.4% GNPX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs GNPX. Trailing 12-month operating profitability (REGN 30.4% vs GNPX 0.0%) and valuation multiples (REGN 14.8x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REGN (10) vs GNPX (0)
Institutional Metric REGN GNPX Criterion Row Winner
Market Capitalization Scale $95.5B $2.2M Larger Scale REGN
Trailing P/E Ratio Valuation 20.4x N/M Lower Multiple REGN
Forward P/E Ratio Valuation 14.8x N/M Lower Multiple REGN
Revenue Growth (YoY) Growth +36.3% +0.0% Higher Growth REGN
Operating Margin (TTM) Profitability 30.4% 0.0% Higher Margin REGN
Net Profit Margin Profitability 28.5% 0.0% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency 14.9% -233.7% Higher ROE REGN
52-Week Range Position Momentum 82% ($592โ€“$992) 11% ($0โ€“$10) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.30ฮฒ ยท 55% Vol -4.68ฮฒ ยท 96% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 46.0 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite REGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REGN vs GNPX Buy Guide
REGN CONSOLIDATION
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GNPX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GNPX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REGN nor GNPX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.